Navigation Links
Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
Date:3/16/2009

t response of treated lesions may be a good predictor of long-term outcome."

Professor Thompson added, "The interim Phase 2 results are also very encouraging, with efficacy and safety as good as or better than those results reported for Phase 1. With the Phase 2 protocol allowing us to treat lesions more than once, we are pleased to report results that are in line with what our expectations have been."

Dr. Craig Dees, PhD, CEO of Provectus concluded, "We are encouraged by these Phase 2 interim results as well as by the improved long-term survival data from Phase 1. With the American Cancer Society estimating that approximately 120,000 patients in the U.S. alone have metastatic melanoma, and the World Health Organization reporting that about 48,000 patients died around the globe from melanoma in 2008, clearly there is a need for a new safe and effective treatment for metastatic melanoma. We look forward to furthering this important research on PV-10 and to communicating detailed Phase 2 interim results at ASCO."

About PV-10

PV-10 is based on a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for nearly fifty years by ophthalmologists and optometrists to assess damage to the eye. It has also been used to detect ailments of the liver. Rose Bengal has an established safety history, a short half-life, and is excreted via the liver and kidneys. Provectus has discovered a novel use for Rose Bengal based on the observation that it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis.

About The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies

The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies, an Oncology CME-Certified Symp
'/>"/>

SOURCE Provectus Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Catylix, Inc. ... Scientific ( Milpitas, California ) announced ... develop and commercialize new fluorination products and related ... has benefited from the use of substituents that ... lipophilicity with polarity to improve binding and bioavailability. ...
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company ... conference call on Thursday, August 14, 2014, at 4:30 p.m. ... June 30, 2014. Financial results will be issued in a ... President and CEO James LaFrance will host the ... Date: Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... Cyberonics, Inc. (Nasdaq: CYBX ) today announced that the ... 23, 2009 of its fiscal year ending April 30, 2010 on ... will conduct a conference call to discuss those results on Thursday, ... Year 2010 Second Quarter Results Conference Call Instructions , ...
... November 6 , - ... for the,Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections , ... focused on the discovery and,development of novel antibiotics designed ... today that its most advanced oral,antibacterial NXL103 (flopristin/linopristin), has ...
Cached Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... US (PRWEB) August 01, 2014 Register to ... one of the most active years on record for life ... in life sciences represented 22 percent of all venture dollars ... exits and achieved high valuations. , However, 2014 is ... a recent report by Silicon Valley Bank, while life sciences ...
(Date:7/31/2014)... Women over the age of 65 face numerous ... greater struggles against poverty and higher rates of asthma ... August issue of Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), outlines the challenges ... practical solutions to improve their care. , ...
(Date:7/31/2014)... The 2013 PolyU TSI hit ... from 75.07 in 2012. The index measures inbound ... integrates them into an overall index. The 2013 ... satisfied with Hong Kong over time. , The ... service performance in Hong Kong are attractions (79.27) ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
Breaking Medicine News(10 mins):Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... At the end of a 10-year, coast-to-coast study of women ... Jr., M.D., and three fellow researchers are making the case ... in their tracks. In the August 2009 issue of ... professor of surgery at Dartmouth Medical School (DMS), and his ...
... Texas Health Science Center at Houston has been awarded a ... a center to conduct innovative cancer research. The center will ... funds totaling $11.6 million over a 5-year period. The new ... The CTO is one of the first 12 Physical Sciences-Oncology ...
... interventional radiologist one Friday night three years ago when he ... Hospital & Clinics. He was asked to attend to a ... to the emergency room with massive blood clots in her ... what happened," said Kuo, assistant professor of radiology at the ...
... all products tested contained lead and some had known skin ... little goblins or vampires are set to paint their faces ... want to think twice, according to a new report released ... by the Campaign for Safe Cosmetics, is titled: Pretty ...
... Oct. 27 Dr. Lawrence Brown of Philadelphia, Pennsylvania has ... national nonprofit organization advocating for children and adolescents with neurologic ... three years. Dr. Brown works for Children,s Hospital of ... 2006. , Dr. Brown,s first order of business will be ...
... Life Extension® the global authority on nutrition, ... of scientific information on anti-aging supplements and therapies, ... with 50 mg of Setria® Glutathione from Kyowa ... available from Life Extension® in 100 count bottles ...
Cached Medicine News:Health News:UT leads collaborative initiative for innovative cancer research 2Health News:UT leads collaborative initiative for innovative cancer research 3Health News:UT leads collaborative initiative for innovative cancer research 4Health News:Stanford study recommends change in treating pulmonary embolisms 2Health News:Stanford study recommends change in treating pulmonary embolisms 3Health News:Stanford study recommends change in treating pulmonary embolisms 4Health News:Toxins Make Halloween Face Paints Scary 2Health News:Toxins Make Halloween Face Paints Scary 3Health News:Dr. Lawrence Brown Named President of the Child Neurology Foundation 2Health News:Life Extension(R) Introduces Glutathione, Cysteine & C Formulation With Setria(R) From Kyowa Hakko USA 2
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
... Tox A/B II is a second-generation rapid ELISA ... and B in fecal specimens. The test utilizes ... detecting not only the more common toxin A+ ... It's easy to perform, produces no indeterminates and ...
Medicine Products: